Tumor burden and heterogenous treatment effect of apalutamide in metastatic castration‐sensitive prostate cancer

NCT02489318 PLAIN LANGUAGE SUMMARY: In an analysis of individual participant data from a trial (the TITAN trial) in patients with metastatic (spreading) castration-sensitive prostate cancer, treatment intensification based on the addition new drugs to standard androgen-deprivation therapy (ADT) was analyzed and compared with the effects in patients who received only standard ADT. Compared with ADT alone, the survival benefit of adding the new drug apalutamide to standard ADT varied according to the number of bone metastases, but no association was observed between the spread of cancer to soft tissues and organs and a survival benefit from adding apalutamide. The results indicate that counting the number of bone metastases may help identify which patients with metastatic castration-sensitive prostate cancer are optimal candidates for treatment intensification with the addition of apalutamide to standard ADT.

Authors

Institutions

Publication Details

Journal
Cancer
Published
2025-03-19
DOI
https://doi.org/10.1002/cncr.35819
Citations
3
Primary Topic
Prostate Cancer Treatment and Research
Type
article
Field-Weighted Citation Impact
4.56
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Tumor burden and heterogenous treatment effect of apalutamide in metastatic castration‐sensitive prostate cancer

Paweł Rajwa, Nobuaki Matsubara, Fumihiko Urabe, Akihiro Hirakawa et al.
3 citations
Cancer
Prostate Cancer Treatment and Research
4.56
article

Tumor burden and heterogenous treatment effect of apalutamide in metastatic castration‐sensitive prostate cancer

Paweł Rajwa, Nobuaki Matsubara, Fumihiko Urabe, Akihiro Hirakawa, Wataru Fukuokaya, Takafumi Yanagisawa, Takahiro Kimura, Alberto Briganti, Shahrokh F Shariat, Keiichiro Mori
article en
3 citations

Abstract

NCT02489318 PLAIN LANGUAGE SUMMARY: In an analysis of individual participant data from a trial (the TITAN trial) in patients with metastatic (spreading) castration-sensitive prostate cancer, treatment intensification based on the addition new drugs to standard androgen-deprivation therapy (ADT) was analyzed and compared with the effects in patients who received only standard ADT. Compared with ADT alone, the survival benefit of adding the new drug apalutamide to standard ADT varied according to the number of bone metastases, but no association was observed between the spread of cancer to soft tissues and organs and a survival benefit from adding apalutamide. The results indicate that counting the number of bone metastases may help identify which patients with metastatic castration-sensitive prostate cancer are optimal candidates for treatment intensification with the addition of apalutamide to standard ADT.

CancerVol. 131(7)
Jikei University School of Medicine (JP), Vita-Salute San Raffaele University (IT), Cornell University (US), Charles University (CZ), Comprehensive Cancer Center Vienna (AT), Postgraduate School of Molecular Medicine (PL), National Cancer Center Hospital East (JP), Karl Landsteiner Society (AT), University College London (GB), Medical University of Vienna (AT), The University of Texas Southwestern Medical Center (US)
Good health and well-being
Openalex Percentile: Top 6%
Prostate Cancer Treatment and Research
4.56
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.